Skip to content

GLP-1 receptor agonists improvement of constitution in overweight and obese patients with T2DM

A clinical study on the constitution improvement of GLP-1 receptor agonist in overweight and obese patients with T2DM

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17010825
Enrollment
Unknown
Registered
2017-03-09
Start date
2017-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overweight and obese patients with T2DM

Interventions

1:Metformin or metformin + sulfonylurea
2:Exenatide

Sponsors

Department of Endocrinology, Xinqiao Hospital of Chongqing City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Type2 diabetes: diagnostic criteria for 1999 WHO diabetes diagnostic criteria 2. overweight and obese BMI=24.0kg/m2. 3. aged 18-65 years old; 4. glycosylated hemoglobin: 7.0%<HbA1c <9.0%; 5. no complications: diabetic retinopathy, nephropathy and neuropathy.

Exclusion criteria

Exclusion criteria: In any of the following circumstances, exclusion. (1) hyperthyroidism; (2) patients with short life expectancy, such as malignant tumors; (3) severe complications of diabetes mellitus; (4) all kinds of serious chronic diseases or hepatic and renal insufficiency; (5) the patients with poor compliance (not to ensure the completion of the 24 week intervention and during the follow-up visit); (6) patients with insulin or insulin; (7) systemic corticosteroids or diet pills; (8) acute diabetic complications, such as infection; (9) other endocrine diseases; (10) the episode of acute pancreatitis, pancreatic cancer, multiple endocrine neoplasia type 2 syndrome, or medullary thyroid carcinoma; (11) inflammatory bowel disease or diabetic gastroparesis. (12) organ transplants or major surgery, trauma, etc in February. (13) the exenatide allergic patients

Design outcomes

Primary

MeasureTime frame
body fat;glucose;glycosylated hemoglobin;blood lipid level;Inflammatory markers;

Countries

China

Contacts

Public ContactJing Xu

Department of Endocrinology, Xinqiao Hospital of Chongqing City

13512380018@163.com+86 13512380018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026